Trial
NCT01754870
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Wisconsin, Madison
Collaborators
Celgene Corporation; Genentech, Inc.
Condition
Chronic Lymphocytic Leukemia (CLL)
Intervention
Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance
Why stopped
slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-15